View in EDS

Effect of monthly intermittent preventive treatment with dihydroartemisinin–piperaquine with and without azithromycin versus monthly sulfadoxine–pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial

Saved in:
Bibliographic Details
Title: Effect of monthly intermittent preventive treatment with dihydroartemisinin–piperaquine with and without azithromycin versus monthly sulfadoxine–pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial
Authors: Madanitsa, Mwayiwawo (AUTHOR), Barsosio, Hellen C (AUTHOR), Minja, Daniel T R (AUTHOR), Mtove, George (AUTHOR), Kavishe, Reginald A (AUTHOR), Dodd, James (AUTHOR), Saidi, Queen (AUTHOR), Onyango, Eric D (AUTHOR), Otieno, Kephas (AUTHOR), Wang, Duolao (AUTHOR), Ashorn, Ulla (AUTHOR), Hill, Jenny (AUTHOR), Mukerebe, Crispin (AUTHOR), Gesase, Samwel (AUTHOR), Msemo, Omari A (AUTHOR), Mwapasa, Victor (AUTHOR), Phiri, Kamija S (AUTHOR), Maleta, Kenneth (AUTHOR), Klein, Nigel (AUTHOR), Magnussen, Pascal (AUTHOR)
Source: Lancet. Mar2023, Vol. 401 Issue 10381, p1020-1036. 17p.
Subjects: Pregnancy outcomes, Small for gestational age, Azithromycin, Neonatal death
Abstract: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin–piperaquine is more effective than IPTp with sulfadoxine–pyrimethamine at reducing malaria infection during pregnancy in areas with high-grade resistance to sulfadoxine–pyrimethamine by Plasmodium falciparum in east Africa. We aimed to assess whether IPTp with dihydroartemisinin–piperaquine, alone or combined with azithromycin, can reduce adverse pregnancy outcomes compared with IPTp with sulfadoxine–pyrimethamine. We did an individually randomised, double-blind, three-arm, partly placebo-controlled trial in areas of high sulfadoxine–pyrimethamine resistance in Kenya, Malawi, and Tanzania. HIV-negative women with a viable singleton pregnancy were randomly assigned (1:1:1) by computer-generated block randomisation, stratified by site and gravidity, to receive monthly IPTp with sulfadoxine–pyrimethamine (500 mg of sulfadoxine and 25 mg of pyrimethamine for 1 day), monthly IPTp with dihydroartemisinin–piperaquine (dosed by weight; three to five tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine once daily for 3 consecutive days) plus a single treatment course of placebo, or monthly IPTp with dihydroartemisinin–piperaquine plus a single treatment course of azithromycin (two tablets containing 500 mg once daily for 2 consecutive days). Outcome assessors in the delivery units were masked to treatment group. The composite primary endpoint was adverse pregnancy outcome, defined as fetal loss, adverse newborn baby outcomes (small for gestational age, low birthweight, or preterm), or neonatal death. The primary analysis was by modified intention to treat, consisting of all randomised participants with primary endpoint data. Women who received at least one dose of study drug were included in the safety analyses. This trial is registered with ClinicalTrials.gov , NCT03208179. From March-29, 2018, to July 5, 2019, 4680 women (mean age 25·0 years [SD 6·0]) were enrolled and randomly assigned: 1561 (33%; mean age 24·9 years [SD 6·1]) to the sulfadoxine–pyrimethamine group, 1561 (33%; mean age 25·1 years [6·1]) to the dihydroartemisinin–piperaquine group, and 1558 (33%; mean age 24·9 years [6.0]) to the dihydroartemisinin–piperaquine plus azithromycin group. Compared with 335 (23·3%) of 1435 women in the sulfadoxine–pyrimethamine group, the primary composite endpoint of adverse pregnancy outcomes was reported more frequently in the dihydroartemisinin–piperaquine group (403 [27·9%] of 1442; risk ratio 1·20, 95% CI 1·06–1·36; p=0·0040) and in the dihydroartemisinin–piperaquine plus azithromycin group (396 [27·6%] of 1433; 1·16, 1·03–1·32; p=0·017). The incidence of serious adverse events was similar in mothers (sulfadoxine–pyrimethamine group 17·7 per 100 person-years, dihydroartemisinin–piperaquine group 14·8 per 100 person-years, and dihydroartemisinin–piperaquine plus azithromycin group 16·9 per 100 person-years) and infants (sulfadoxine–pyrimethamine group 49·2 per 100 person-years, dihydroartemisinin–piperaquine group 42·4 per 100 person-years, and dihydroartemisinin–piperaquine plus azithromycin group 47·8 per 100 person-years) across treatment groups. 12 (0·2%) of 6685 sulfadoxine–pyrimethamine, 19 (0·3%) of 7014 dihydroartemisinin–piperaquine, and 23 (0·3%) of 6849 dihydroartemisinin–piperaquine plus azithromycin treatment courses were vomited within 30 min. Monthly IPTp with dihydroartemisinin–piperaquine did not improve pregnancy outcomes, and the addition of a single course of azithromycin did not enhance the effect of monthly IPTp with dihydroartemisinin–piperaquine. Trials that combine sulfadoxine–pyrimethamine and dihydroartemisinin–piperaquine for IPTp should be considered. European & Developing Countries Clinical Trials Partnership 2, supported by the EU, and the UK Joint-Global-Health-Trials-Scheme of the Foreign, Commonwealth and Development Office, Medical Research Council, Department of Health and Social Care, Wellcome, and the Bill-&-Melinda-Gates-Foundation. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 162636819
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effect of monthly intermittent preventive treatment with dihydroartemisinin–piperaquine with and without azithromycin versus monthly sulfadoxine–pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Madanitsa%2C+Mwayiwawo%22">Madanitsa, Mwayiwawo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Barsosio%2C+Hellen+C%22">Barsosio, Hellen C</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Minja%2C+Daniel+T+R%22">Minja, Daniel T R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mtove%2C+George%22">Mtove, George</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kavishe%2C+Reginald+A%22">Kavishe, Reginald A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dodd%2C+James%22">Dodd, James</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Saidi%2C+Queen%22">Saidi, Queen</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Onyango%2C+Eric+D%22">Onyango, Eric D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Otieno%2C+Kephas%22">Otieno, Kephas</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+Duolao%22">Wang, Duolao</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ashorn%2C+Ulla%22">Ashorn, Ulla</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hill%2C+Jenny%22">Hill, Jenny</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mukerebe%2C+Crispin%22">Mukerebe, Crispin</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gesase%2C+Samwel%22">Gesase, Samwel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Msemo%2C+Omari+A%22">Msemo, Omari A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mwapasa%2C+Victor%22">Mwapasa, Victor</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Phiri%2C+Kamija+S%22">Phiri, Kamija S</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Maleta%2C+Kenneth%22">Maleta, Kenneth</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Klein%2C+Nigel%22">Klein, Nigel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Magnussen%2C+Pascal%22">Magnussen, Pascal</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. Mar2023, Vol. 401 Issue 10381, p1020-1036. 17p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Pregnancy+outcomes%22">Pregnancy outcomes</searchLink><br /><searchLink fieldCode="DE" term="%22Small+for+gestational+age%22">Small for gestational age</searchLink><br /><searchLink fieldCode="DE" term="%22Azithromycin%22">Azithromycin</searchLink><br /><searchLink fieldCode="DE" term="%22Neonatal+death%22">Neonatal death</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin–piperaquine is more effective than IPTp with sulfadoxine–pyrimethamine at reducing malaria infection during pregnancy in areas with high-grade resistance to sulfadoxine–pyrimethamine by Plasmodium falciparum in east Africa. We aimed to assess whether IPTp with dihydroartemisinin–piperaquine, alone or combined with azithromycin, can reduce adverse pregnancy outcomes compared with IPTp with sulfadoxine–pyrimethamine. We did an individually randomised, double-blind, three-arm, partly placebo-controlled trial in areas of high sulfadoxine–pyrimethamine resistance in Kenya, Malawi, and Tanzania. HIV-negative women with a viable singleton pregnancy were randomly assigned (1:1:1) by computer-generated block randomisation, stratified by site and gravidity, to receive monthly IPTp with sulfadoxine–pyrimethamine (500 mg of sulfadoxine and 25 mg of pyrimethamine for 1 day), monthly IPTp with dihydroartemisinin–piperaquine (dosed by weight; three to five tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine once daily for 3 consecutive days) plus a single treatment course of placebo, or monthly IPTp with dihydroartemisinin–piperaquine plus a single treatment course of azithromycin (two tablets containing 500 mg once daily for 2 consecutive days). Outcome assessors in the delivery units were masked to treatment group. The composite primary endpoint was adverse pregnancy outcome, defined as fetal loss, adverse newborn baby outcomes (small for gestational age, low birthweight, or preterm), or neonatal death. The primary analysis was by modified intention to treat, consisting of all randomised participants with primary endpoint data. Women who received at least one dose of study drug were included in the safety analyses. This trial is registered with ClinicalTrials.gov , NCT03208179. From March-29, 2018, to July 5, 2019, 4680 women (mean age 25·0 years [SD 6·0]) were enrolled and randomly assigned: 1561 (33%; mean age 24·9 years [SD 6·1]) to the sulfadoxine–pyrimethamine group, 1561 (33%; mean age 25·1 years [6·1]) to the dihydroartemisinin–piperaquine group, and 1558 (33%; mean age 24·9 years [6.0]) to the dihydroartemisinin–piperaquine plus azithromycin group. Compared with 335 (23·3%) of 1435 women in the sulfadoxine–pyrimethamine group, the primary composite endpoint of adverse pregnancy outcomes was reported more frequently in the dihydroartemisinin–piperaquine group (403 [27·9%] of 1442; risk ratio 1·20, 95% CI 1·06–1·36; p=0·0040) and in the dihydroartemisinin–piperaquine plus azithromycin group (396 [27·6%] of 1433; 1·16, 1·03–1·32; p=0·017). The incidence of serious adverse events was similar in mothers (sulfadoxine–pyrimethamine group 17·7 per 100 person-years, dihydroartemisinin–piperaquine group 14·8 per 100 person-years, and dihydroartemisinin–piperaquine plus azithromycin group 16·9 per 100 person-years) and infants (sulfadoxine–pyrimethamine group 49·2 per 100 person-years, dihydroartemisinin–piperaquine group 42·4 per 100 person-years, and dihydroartemisinin–piperaquine plus azithromycin group 47·8 per 100 person-years) across treatment groups. 12 (0·2%) of 6685 sulfadoxine–pyrimethamine, 19 (0·3%) of 7014 dihydroartemisinin–piperaquine, and 23 (0·3%) of 6849 dihydroartemisinin–piperaquine plus azithromycin treatment courses were vomited within 30 min. Monthly IPTp with dihydroartemisinin–piperaquine did not improve pregnancy outcomes, and the addition of a single course of azithromycin did not enhance the effect of monthly IPTp with dihydroartemisinin–piperaquine. Trials that combine sulfadoxine–pyrimethamine and dihydroartemisinin–piperaquine for IPTp should be considered. European & Developing Countries Clinical Trials Partnership 2, supported by the EU, and the UK Joint-Global-Health-Trials-Scheme of the Foreign, Commonwealth and Development Office, Medical Research Council, Department of Health and Social Care, Wellcome, and the Bill-&-Melinda-Gates-Foundation. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=162636819
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(22)02535-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 17
        StartPage: 1020
    Subjects:
      – SubjectFull: Pregnancy outcomes
        Type: general
      – SubjectFull: Small for gestational age
        Type: general
      – SubjectFull: Azithromycin
        Type: general
      – SubjectFull: Neonatal death
        Type: general
    Titles:
      – TitleFull: Effect of monthly intermittent preventive treatment with dihydroartemisinin–piperaquine with and without azithromycin versus monthly sulfadoxine–pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Madanitsa, Mwayiwawo
      – PersonEntity:
          Name:
            NameFull: Barsosio, Hellen C
      – PersonEntity:
          Name:
            NameFull: Minja, Daniel T R
      – PersonEntity:
          Name:
            NameFull: Mtove, George
      – PersonEntity:
          Name:
            NameFull: Kavishe, Reginald A
      – PersonEntity:
          Name:
            NameFull: Dodd, James
      – PersonEntity:
          Name:
            NameFull: Saidi, Queen
      – PersonEntity:
          Name:
            NameFull: Onyango, Eric D
      – PersonEntity:
          Name:
            NameFull: Otieno, Kephas
      – PersonEntity:
          Name:
            NameFull: Wang, Duolao
      – PersonEntity:
          Name:
            NameFull: Ashorn, Ulla
      – PersonEntity:
          Name:
            NameFull: Hill, Jenny
      – PersonEntity:
          Name:
            NameFull: Mukerebe, Crispin
      – PersonEntity:
          Name:
            NameFull: Gesase, Samwel
      – PersonEntity:
          Name:
            NameFull: Msemo, Omari A
      – PersonEntity:
          Name:
            NameFull: Mwapasa, Victor
      – PersonEntity:
          Name:
            NameFull: Phiri, Kamija S
      – PersonEntity:
          Name:
            NameFull: Maleta, Kenneth
      – PersonEntity:
          Name:
            NameFull: Klein, Nigel
      – PersonEntity:
          Name:
            NameFull: Magnussen, Pascal
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 03
              Text: Mar2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 401
            – Type: issue
              Value: 10381
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1